Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Four new special agents in charge have been appointed to the FBI’s Washington Field Office, and a fifth has shifted to another leadership position within the office. Michael H. Glasheen was named ...